Loading
This study tests a PARP inhibitor; the registry reports that it is active not recruiting.
The registry lists NCT04644068 as active not recruiting, last updated 2026-09-21. Enrolment is 702 actual participants. Interventions: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant. Primary measures include The number of subjects with adverse events/serious adverse events; The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca, Ovarian cancer.
Shares Saruparib, PARP, Ovarian cancer, Non-small-cell lung cancer.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, Small-cell lung cancer.
Shares Saruparib, PARP, Ovarian cancer.
Shares Saruparib, PARP, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/